BMS gives back eroded Plavix/Avapro rights to Sanofi
This article was originally published in Scrip
Executive Summary
It was good while it lasted, but the products at the heart of the marketing alliance between Bristol-Myers Squibb and Sanofi have now fallen to generic competition, and the firms have revised their long-standing agreement. BMS says the new arrangement will allow it to focus on newer products coming out of its pipeline.